必要な CMO / CDMO を検索して見つける
貴社の医薬品開発および製造プロジェクトのための高度なスキルを持つパートナーを見つけてください。
治療専門分野 (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones
OEB (職業性暴露バンディング): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
市場: NMPA (China), FDA (USA)
地域: アジア太平洋
コンプライアンス: FDA (cGMP), ISO, NMPA (China GMP)
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
カテゴリ / 製品: 化学合成品
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services
治療専門分野 (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), TGA (Australia)
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), PMDA/MHLW (Japan GMP), TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
カテゴリ / 製品: 化学合成品
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services
OEB (職業性暴露バンディング): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
治療専門分野 (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), MHRA (UK), MFDS (South Korea), TGA (Australia)
コンプライアンス: FDA (cGMP), ISO, ECOVADIS
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
カテゴリ / 製品: 化学合成品
サービス: Development services, Manufacturing services
OEB (職業性暴露バンディング): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
地域: 北米
市場: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: ヨーロッパ
コンプライアンス: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
BSL (生物学的安全性レベル): 1, 2
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
カテゴリ / 製品: 生物製剤, FDF / 医薬品
市場: EMA (EU), MHRA (UK), TGA (Australia)
地域: ヨーロッパ
使用: Human, Veterinary
BSL (生物学的安全性レベル): 1
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
OEB (職業性暴露バンディング): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
バッチサイズ: Small, Medium
コンプライアンス: EMA (EU GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)
カテゴリ / 製品: FDF / 医薬品
BSL (生物学的安全性レベル): 3, 1, 2
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
コンプライアンス: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MFDS/KFDA (Republic of Korea GMP)
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
規制物質: Lowest potential for abuse
OEB (職業性暴露バンディング): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
地域: 北米
カテゴリ / 製品: FDF / 医薬品
53Biologics Production Plant
53Biologics
53Biologics は、DNA からタンパク質に至る生物製剤の生産の解読を専門とするスペインの CDMO です。
市場: EMA (EU), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), TGA (Australia)
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
BSL (生物学的安全性レベル): 1, 2
カテゴリ / 製品: 生物製剤
市場: EMA (EU), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), TGA (Australia)
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Regulatory services
地域: ヨーロッパ
コンプライアンス: ISO
BSL (生物学的安全性レベル): 1
バッチサイズ: Small, Medium
カテゴリ / 製品: 生物製剤
市場: EMA (EU), FDA (USA), ANVISA (Brazil), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)
サービス: Logistics, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
治療専門分野 (ATC): (C) Cardiovascular system, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (N) Nervous system, (A) Digestive tract and metabolism
規制物質: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
カテゴリ / 製品: FDF / 医薬品
OEB (職業性暴露バンディング): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: ヨーロッパ
コンプライアンス: ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)
バッチサイズ: Large, Small, Medium
使用: Human
BSL (生物学的安全性レベル): 1, 2
治療専門分野 (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins, (L) Antineoplastic and immunomodulating agents, (N) Nervous system
カテゴリ / 製品: FDF / 医薬品
ALPHAVET Zrt.- Bábolna Manufacturing Plant
Alphavet Zrt.
この工場は EU GMP 認定を受けており、EU 加盟国 18 か国および EU 域外の他のヨーロッパ 7 か国向けに動物用医薬品を生産しています。
市場: EMA (EU)
地域: ヨーロッパ
コンプライアンス: ISO, EMA (EU GMP)
バッチサイズ: Large, Medium
カテゴリ / 製品: 栄養補助食品, FDF / 医薬品
使用: Veterinary
サービス: Manufacturing services, Analytical / QC services, Regulatory services, Packaging
Avara Pharmaceutical Services | Arecibo Site
AVARA
規制物質 (DEA II V) に関する強力な専門知識を備えた商業規模の経口固形製剤 (OSD) 製造施設。
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
コンプライアンス: ICH, FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), EMA (EU GMP), Health Canada (Canada GMP), MFDS/KFDA (Republic of Korea GMP)
市場: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), Russian Health Authorities, MFDS (South Korea), TGA (Australia)
バッチサイズ: Large, Medium
使用: Human
カテゴリ / 製品: 化学合成品, サービス, FDF / 医薬品, 粒子工学
サービス: Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging
治療専門分野 (ATC): (C) Cardiovascular system, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (R) Respiratory system, (S) Sensory organs, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones
地域: 北米
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)